Literature DB >> 10644891

p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.

S L Lai1, R P Perng, J Hwang.   

Abstract

This study examined the effects of p53 gene status on DNA damage-induced cell death and chemosensitivity to various chemotherapeutic agents in non-small cell lung cancer (NSCLC) cells. A mutant p53 gene was introduced into cells carrying the wild-type p53 gene and also vice versa to introduce the wild-type p53 gene into cells carrying the mutant p53 gene. Chemosensitivity and DNA damage-induced apoptosis in these cells were then examined. This study included five cell lines, NCI-H1437, NCI-H727, NCI-H441 and NCI-H1299 which carry a mutant p53 gene and NCI-H460 which carries a wild-type p53 gene. Mutant p53-carrying cells were transfected with the wild-type p53 gene, while mutant p53 genes were introduced into NCI-H460 cells. These p53 genes were individually mutated at amino acid residues 143, 175, 248 and 273. The representative cell line NCI-H1437 cells transfected with wild-type p53 gene (H1437/wtp53) showed a dramatic increase in susceptibility to three anticancer agents (7-fold to cisplatin, 21-fold to etoposide, and 20-fold to camptothecin) compared to untransfected or neotransfected H1437 cells. An increase in chemosensitivity was also observed in wild-type p53 transfectants of H727, H441, H1299 cells. The results of chemosensitivity were consistent with the observations on apoptotic cell death. H1437/wtp53 cells, but not H1437 parental cells, exhibited a characteristic feature of apoptotic cell death that generated oligonucleosomal-sized DNA fragments. In contrast, loss of chemosensitivity and lack of p53-mediated DNA degradation in response to anticancer agents were observed in H460 cells transfected with mutant p53. These observations suggest that the increase in chemosensitivity was attributable to wild-type p53 mediation of the process of apoptosis. In addition, our results also suggest that p53 gene status modulates the extent of chemosensitivity and the induction of apoptosis by different anticancer agents in NSCLC cells. Copyright 2000 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644891     DOI: 10.1007/bf02255920

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  23 in total

1.  MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53.

Authors:  Imayavaramban Lakshmanan; Shereen Salfity; Parthasarathy Seshacharyulu; Satyanarayana Rachagani; Abigail Thomas; Srustidhar Das; Prabin D Majhi; Rama Krishna Nimmakayala; Raghupathy Vengoji; Subodh M Lele; Moorthy P Ponnusamy; Surinder K Batra; Apar Kishor Ganti
Journal:  Clin Cancer Res       Date:  2017-02-14       Impact factor: 12.531

2.  Time-course analysis of DNA damage response-related genes after in vitro radiation in H460 and H1229 lung cancer cell lines.

Authors:  Kang Ho Kim; Hae Yong Yoo; Kyeung Min Joo; Yong Jung; Juyoun Jin; Yonghyun Kim; Su Jin Yoon; Seung Ho Choi; Ho Jun Seol; Woong Yang Park; Do Hyun Nam
Journal:  Exp Mol Med       Date:  2011-07-30       Impact factor: 8.718

3.  Exploiting evolution to treat drug resistance: combination therapy and the double bind.

Authors:  David Basanta; Robert A Gatenby; Alexander R A Anderson
Journal:  Mol Pharm       Date:  2012-03-19       Impact factor: 4.939

4.  Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Authors:  Richard J Jones; Chad C Bjorklund; Veerabhadran Baladandayuthapani; Deborah J Kuhn; Robert Z Orlowski
Journal:  Mol Cancer Ther       Date:  2012-08-28       Impact factor: 6.261

5.  A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089.

Authors:  Khushboo Sharma; Rachel W Goehe; Xu Di; Mark Anthony Hicks; Suzy V Torti; Frank M Torti; Hisashi Harada; David A Gewirtz
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

6.  Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.

Authors:  Jonathan M Solomon; Rao Pasupuleti; Lei Xu; Thomas McDonagh; Rory Curtis; Peter S DiStefano; L Julie Huber
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

7.  Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.

Authors:  Hongmei Luo; Caroline Yount; Hainan Lang; Aimin Yang; Ellen C Riemer; Katherine Lyons; Kenneth N Vanek; Gerard A Silvestri; Bradley A Schulte; Gavin Y Wang
Journal:  Lung Cancer       Date:  2013-05-16       Impact factor: 5.705

8.  Allele specific gain-of-function activity of p53 mutants in lung cancer cells.

Authors:  Catherine A Vaughan; Rebecca Frum; Isabella Pearsall; Shilpa Singh; Brad Windle; Andrew Yeudall; Swati P Deb; Sumitra Deb
Journal:  Biochem Biophys Res Commun       Date:  2012-09-16       Impact factor: 3.575

9.  Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma.

Authors:  Christopher M Mahaffey; Hongqiao Zhang; Alessandra Rinna; William Holland; Philip C Mack; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2009-04-05       Impact factor: 7.376

10.  Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

Authors:  Catherine A Vaughan; Shilpa Singh; Brad Windle; W Andrew Yeudall; Rebecca Frum; Steven R Grossman; Swati P Deb; Sumitra Deb
Journal:  Genes Cancer       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.